**Metastasis-Directed Therapy (MDT) Overview:** MDT refers to localised treatments aimed specifically at metastatic lesions in patients with cancer. These therapies include techniques such as stereotactic body radiotherapy (SBRT), surgical resection, and thermal ablations (e.
**Metastasis-Directed Therapy (MDT) Overview:**
MDT refers to localised treatments aimed specifically at metastatic lesions in patients with cancer. These therapies include techniques such as stereotactic body radiotherapy (SBRT), surgical resection, and thermal ablations (e.g., radiofrequency or cryoablation). MDT is particularly valuable for patients with oligometastatic disease, where the number of metastases is limited and potentially treatable.
**Utility in Metastatic Disease:**
MDTs have redefined the therapeutic approach to metastatic cancer by offering the possibility of long-term disease control or even cure in select patients. Rather than focusing solely on systemic therapies, MDT targets visible metastatic lesions, suppressing prometastatic signalling and disrupting interlesional communication. Clinical evidence suggests that MDT can delay systemic therapy initiation, extend progression-free survival, and improve overall outcomes when applied iteratively or comprehensively.
Emerging research highlights the importance of treating all visible disease to prevent reseeding and progression. MDT's effectiveness is influenced by factors such as tumour biology, immune phenotype, and metastatic kinetics, underscoring the need for personalised strategies. MDT represents a shift toward transforming metastatic cancer into a manageable or potentially curable condition.
Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international...
Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the...
Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance...
Introduction: Cancer-associated cachexia is a devastating syndrome characterized by loss of appetite, weight loss, and muscle wasting, affecting up to half of patients with lung cancer. This landmark study uncovers a previously unrecognized mechanism linking...
Introduction: Resistance to anti-EGFR therapy has traditionally been considered irreversible in metastatic colorectal cancer (mCRC). However, emerging evidence suggests that resistance is dynamic and can be monitored using circulating tumor DNA (ctDNA). The CAPRI-2 trial...
Introduction: Immune checkpoint inhibitors combined with chemotherapy have become the standard first-line treatment for advanced HER2-negative gastric and gastroesophageal junction cancers. This meta-analysis evaluated whether treatment benefits differ between Asian and non-Asian populations. Why was...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.